Table of Content

1 Postmenopausal Vaginal Atrophy Drugs Market Overview
1.1 Product Overview and Scope of Postmenopausal Vaginal Atrophy Drugs
1.2 Postmenopausal Vaginal Atrophy Drugs Segment by Type
1.2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Value Comparison by Type (2024-2034)
1.2.2 Vaginal Gels
1.2.3 Creams
1.2.4 Tablets
1.2.5 Rings
1.2.6 Patches
1.3 Postmenopausal Vaginal Atrophy Drugs Segment by Application
1.3.1 Global Postmenopausal Vaginal Atrophy Drugs Market Value by Application: (2024-2034)
1.3.2 Offline Stores
1.3.3 Online Stores
1.4 Global Postmenopausal Vaginal Atrophy Drugs Market Size Estimates and Forecasts
1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2018-2034
1.4.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2018-2034
1.4.3 Global Postmenopausal Vaginal Atrophy Drugs Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Postmenopausal Vaginal Atrophy Drugs Market Competition by Manufacturers
2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Postmenopausal Vaginal Atrophy Drugs Industry Ranking 2021 VS 2024 VS 2023
2.5 Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Product Type & Application
2.7 Postmenopausal Vaginal Atrophy Drugs Market Competitive Situation and Trends
2.7.1 Postmenopausal Vaginal Atrophy Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Postmenopausal Vaginal Atrophy Drugs Players Market Share by Revenue
2.7.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario by Region
3.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region: 2018 Versus 2024 Versus 2034
3.2 Global Postmenopausal Vaginal Atrophy Drugs Global Postmenopausal Vaginal Atrophy Drugs Sales by Region: 2018-2034
3.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region: 2018-2023
3.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region: 2024-2034
3.3 Global Postmenopausal Vaginal Atrophy Drugs Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region: 2018-2034
3.3.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region: 2018-2023
3.3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region: 2024-2034
3.4 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.4.1 North America Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.4.2 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2034)
3.4.3 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2018-2034)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.5.1 Europe Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.5.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2034)
3.5.3 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.6.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2034)
3.6.3 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.7.1 Latin America Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.7.2 Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2034)
3.7.3 Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2018 VS 2024 VS 2034
3.8.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2034)
3.8.3 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2018-2034)
4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2018-2023)
4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2024-2034)
4.1.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2018-2034)
4.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2018-2034)
4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2018-2023)
4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2024-2034)
4.2.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2018-2034)
5 Segment by Application
5.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2034)
5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2023)
5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2024-2034)
5.1.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2018-2034)
5.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2018-2034)
5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2018-2023)
5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2024-2034)
5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Actavis plc
6.1.1 Actavis plc Corporation Information
6.1.2 Actavis plc Description and Business Overview
6.1.3 Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.1.5 Actavis plc Recent Developments/Updates
6.2 Bionovo, Inc.
6.2.1 Bionovo, Inc. Corporation Information
6.2.2 Bionovo, Inc. Description and Business Overview
6.2.3 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.2.5 Bionovo, Inc. Recent Developments/Updates
6.3 Endoceutics, Inc.
6.3.1 Endoceutics, Inc. Corporation Information
6.3.2 Endoceutics, Inc. Description and Business Overview
6.3.3 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.3.5 Endoceutics, Inc. Recent Developments/Updates
6.4 Novo Nordisk A/S
6.4.1 Novo Nordisk A/S Corporation Information
6.4.2 Novo Nordisk A/S Description and Business Overview
6.4.3 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.4.5 Novo Nordisk A/S Recent Developments/Updates
6.5 Pfizer Inc.
6.5.1 Pfizer Inc. Corporation Information
6.5.2 Pfizer Inc. Description and Business Overview
6.5.3 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.5.5 Pfizer Inc. Recent Developments/Updates
6.6 Teva Pharmaceuticals Ltd.
6.6.1 Teva Pharmaceuticals Ltd. Corporation Information
6.6.2 Teva Pharmaceuticals Ltd. Description and Business Overview
6.6.3 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.6.5 Teva Pharmaceuticals Ltd. Recent Developments/Updates
6.7 Therapeutics MD, Inc.
6.6.1 Therapeutics MD, Inc. Corporation Information
6.6.2 Therapeutics MD, Inc. Description and Business Overview
6.6.3 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.7.5 Therapeutics MD, Inc. Recent Developments/Updates
6.8 Shionogi & Company
6.8.1 Shionogi & Company Corporation Information
6.8.2 Shionogi & Company Description and Business Overview
6.8.3 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.8.5 Shionogi & Company Recent Developments/Updates
6.9 Allergan plc
6.9.1 Allergan plc Corporation Information
6.9.2 Allergan plc Description and Business Overview
6.9.3 Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.9.5 Allergan plc Recent Developments/Updates
6.10 Shionogi & Co. Ltd.
6.10.1 Shionogi & Co. Ltd. Corporation Information
6.10.2 Shionogi & Co. Ltd. Description and Business Overview
6.10.3 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.10.5 Shionogi & Co. Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Postmenopausal Vaginal Atrophy Drugs Industry Chain Analysis
7.2 Postmenopausal Vaginal Atrophy Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Postmenopausal Vaginal Atrophy Drugs Production Mode & Process
7.4 Postmenopausal Vaginal Atrophy Drugs Sales and Marketing
7.4.1 Postmenopausal Vaginal Atrophy Drugs Sales Channels
7.4.2 Postmenopausal Vaginal Atrophy Drugs Distributors
7.5 Postmenopausal Vaginal Atrophy Drugs Customers
8 Postmenopausal Vaginal Atrophy Drugs Market Dynamics
8.1 Postmenopausal Vaginal Atrophy Drugs Industry Trends
8.2 Postmenopausal Vaginal Atrophy Drugs Market Drivers
8.3 Postmenopausal Vaginal Atrophy Drugs Market Challenges
8.4 Postmenopausal Vaginal Atrophy Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Postmenopausal Vaginal Atrophy Drugs Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Postmenopausal Vaginal Atrophy Drugs Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Postmenopausal Vaginal Atrophy Drugs Market Competitive Situation by Manufacturers in 2024
Table 4. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Postmenopausal Vaginal Atrophy Drugs Average Price (USD/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Postmenopausal Vaginal Atrophy Drugs, Industry Ranking, 2021 VS 2024 VS 2023
Table 10. Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Postmenopausal Vaginal Atrophy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 17. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2018-2023) & (K Units)
Table 18. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2018-2023)
Table 19. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2024-2034) & (K Units)
Table 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2024-2034)
Table 21. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2018-2023)
Table 23. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2024-2034)
Table 25. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 26. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2023) & (K Units)
Table 27. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2024-2034) & (K Units)
Table 28. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 31. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2023) & (K Units)
Table 32. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2024-2034) & (K Units)
Table 33. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 36. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 41. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 46. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2018-2023)
Table 51. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2024-2034)
Table 52. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2018-2023)
Table 53. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2024-2034)
Table 54. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2018-2023)
Table 57. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2024-2034)
Table 58. Global Postmenopausal Vaginal Atrophy Drugs Price (USD/Unit) by Type (2018-2023)
Table 59. Global Postmenopausal Vaginal Atrophy Drugs Price (USD/Unit) by Type (2024-2034)
Table 60. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2018-2023)
Table 61. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2024-2034)
Table 62. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2018-2023)
Table 63. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2024-2034)
Table 64. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2018-2023)
Table 67. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2024-2034)
Table 68. Global Postmenopausal Vaginal Atrophy Drugs Price (USD/Unit) by Application (2018-2023)
Table 69. Global Postmenopausal Vaginal Atrophy Drugs Price (USD/Unit) by Application (2024-2034)
Table 70. Actavis plc Corporation Information
Table 71. Actavis plc Description and Business Overview
Table 72. Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 73. Actavis plc Postmenopausal Vaginal Atrophy Drugs Product
Table 74. Actavis plc Recent Developments/Updates
Table 75. Bionovo, Inc. Corporation Information
Table 76. Bionovo, Inc. Description and Business Overview
Table 77. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 78. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Product
Table 79. Bionovo, Inc. Recent Developments/Updates
Table 80. Endoceutics, Inc. Corporation Information
Table 81. Endoceutics, Inc. Description and Business Overview
Table 82. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 83. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Product
Table 84. Endoceutics, Inc. Recent Developments/Updates
Table 85. Novo Nordisk A/S Corporation Information
Table 86. Novo Nordisk A/S Description and Business Overview
Table 87. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 88. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Product
Table 89. Novo Nordisk A/S Recent Developments/Updates
Table 90. Pfizer Inc. Corporation Information
Table 91. Pfizer Inc. Description and Business Overview
Table 92. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 93. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Product
Table 94. Pfizer Inc. Recent Developments/Updates
Table 95. Teva Pharmaceuticals Ltd. Corporation Information
Table 96. Teva Pharmaceuticals Ltd. Description and Business Overview
Table 97. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 98. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Product
Table 99. Teva Pharmaceuticals Ltd. Recent Developments/Updates
Table 100. Therapeutics MD, Inc. Corporation Information
Table 101. Therapeutics MD, Inc. Description and Business Overview
Table 102. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 103. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Product
Table 104. Therapeutics MD, Inc. Recent Developments/Updates
Table 105. Shionogi & Company Corporation Information
Table 106. Shionogi & Company Description and Business Overview
Table 107. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 108. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Product
Table 109. Shionogi & Company Recent Developments/Updates
Table 110. Allergan plc Corporation Information
Table 111. Allergan plc Description and Business Overview
Table 112. Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 113. Allergan plc Postmenopausal Vaginal Atrophy Drugs Product
Table 114. Allergan plc Recent Developments/Updates
Table 115. Shionogi & Co. Ltd. Corporation Information
Table 116. Shionogi & Co. Ltd. Description and Business Overview
Table 117. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 118. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Product
Table 119. Shionogi & Co. Ltd. Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Postmenopausal Vaginal Atrophy Drugs Distributors List
Table 123. Postmenopausal Vaginal Atrophy Drugs Customers List
Table 124. Postmenopausal Vaginal Atrophy Drugs Market Trends
Table 125. Postmenopausal Vaginal Atrophy Drugs Market Drivers
Table 126. Postmenopausal Vaginal Atrophy Drugs Market Challenges
Table 127. Postmenopausal Vaginal Atrophy Drugs Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Postmenopausal Vaginal Atrophy Drugs
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2024 & 2034
Figure 4. Vaginal Gels Product Picture
Figure 5. Creams Product Picture
Figure 6. Tablets Product Picture
Figure 7. Rings Product Picture
Figure 8. Patches Product Picture
Figure 9. Global Postmenopausal Vaginal Atrophy Drugs Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 10. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2024 & 2034
Figure 11. Offline Stores
Figure 12. Online Stores
Figure 13. Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Market Size (2018-2034) & (US$ Million)
Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Sales (2018-2034) & (K Units)
Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Average Price (USD/Unit) & (2018-2034)
Figure 17. Postmenopausal Vaginal Atrophy Drugs Report Years Considered
Figure 18. Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturers in 2024
Figure 19. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers in 2024
Figure 20. The Global 5 and 10 Largest Postmenopausal Vaginal Atrophy Drugs Players: Market Share by Revenue in 2024
Figure 21. Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2024
Figure 22. Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Figure 23. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2018-2034)
Figure 24. North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2018-2034)
Figure 25. U.S. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 26. Canada Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 27. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2018-2034)
Figure 28. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2018-2034)
Figure 29. Germany Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 30. France Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. U.K. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. Italy Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. Russia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 34. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2018-2034)
Figure 35. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2018-2034)
Figure 36. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. Japan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. South Korea Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. India Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. Australia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. Taiwan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Indonesia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. Thailand Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Malaysia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Philippines Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2018-2034)
Figure 47. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2018-2034)
Figure 48. Mexico Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 49. Brazil Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. Argentina Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 51. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2018-2034)
Figure 52. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2018-2034)
Figure 53. Turkey Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 54. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 55. U.A.E Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 56. Global Sales Market Share of Postmenopausal Vaginal Atrophy Drugs by Type (2018-2034)
Figure 57. Global Revenue Market Share of Postmenopausal Vaginal Atrophy Drugs by Type (2018-2034)
Figure 58. Global Postmenopausal Vaginal Atrophy Drugs Price (USD/Unit) by Type (2018-2034)
Figure 59. Global Sales Market Share of Postmenopausal Vaginal Atrophy Drugs by Application (2018-2034)
Figure 60. Global Revenue Market Share of Postmenopausal Vaginal Atrophy Drugs by Application (2018-2034)
Figure 61. Global Postmenopausal Vaginal Atrophy Drugs Price (USD/Unit) by Application (2018-2034)
Figure 62. Postmenopausal Vaginal Atrophy Drugs Value Chain
Figure 63. Postmenopausal Vaginal Atrophy Drugs Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed